Physician

Krishi Venkata Peddada, M.D.

According to 2025 Medicare claims, Krishi Peddada, M.D. (NPI: 1588014393) practices ophthalmology in the Greenville-Anderson-Greer, SC market, with the plurality of this provider's patient population coming from Greenville, SC. This provider's primary affiliated billing organization is CLEMSON EYE, PA (NPI: 1447383831; TIN: 582283225) and primary practice location at 29680-7132. Peddada is affiliated with the CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under the REACH model.

Peddada's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 767 traditional Medicare patients, billed 72,193 HCPCS/CPT codes, and received $4,190,793 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 416 prescription claims across 136 beneficiaries totaling $48,793 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 48 records totaling $2,966. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $4,818 to $4,190,793. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,182 and ending at $48,793. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$2.1M$4.2M2020 Medicare payment: $4,818 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $12,225 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $551,409 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,345,209 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $4,190,793 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
20203248$4,818
202171127$12,225
20223312,520$551,409
20235439,082$1,345,209
202476772,193$4,190,793

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$32K$64K2016 Drug cost: $1,182 (USD; Tot_Drug_Cst)2017 Drug cost: $20,488 (USD; Tot_Drug_Cst)2018 Drug cost: $64,338 (USD; Tot_Drug_Cst)2019 Drug cost: $16,157 (USD; Tot_Drug_Cst)2020 Drug cost: $15,163 (USD; Tot_Drug_Cst)2021 Drug cost: $21,039 (USD; Tot_Drug_Cst)2022 Drug cost: $22,418 (USD; Tot_Drug_Cst)2023 Drug cost: $28,287 (USD; Tot_Drug_Cst)2024 Drug cost: $48,793 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
20161632$1,182
201788175$20,488
2018126478$64,338
201959148$16,157
202063171$15,163
2021116298$21,039
2022105273$22,418
2023118358$28,287
2024136416$48,793

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg2512,376$655
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more430496$95
67028Injection of drug into eye3712,106$93
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more5021,046$64
92134Imaging of retina7112,824$30

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate802,898$3,482
Brimonidine TartrateBrimonidine Tartrate261,408$2,898
DifluprednateDifluprednate15378$2,001
Ketorolac TromethamineKetorolac Tromethamine33995$2,000
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13331$1,159

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.48$2,966Carl Zeiss Meditec USA, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Krishi Venkata Peddada, M.D.?

Tedicare shows public-source Medicare data for Krishi Venkata Peddada, M.D. (NPI 1588014393), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Krishi Venkata Peddada, M.D. have ACO affiliation data?

Krishi Venkata Peddada, M.D. is shown with ACO affiliation data for CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Krishi Venkata Peddada, M.D.?

Krishi Venkata Peddada, M.D. is linked to CLEMSON EYE, PA (billing NPI 1447383831) in the available physician profile data.

Does Krishi Venkata Peddada, M.D. have Open Payments data?

Krishi Venkata Peddada, M.D. has 48 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.